Vir Biotechnology prices $150M stock offering
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vir Biotechnology, Inc. (VIR) priced an underwritten public offering of 15,000,000 common shares at $10.00 per share. The company expects gross proceeds of $150 million and net proceeds of approximately $140.4 million after underwriting discounts, commissions and estimated offering expenses.
Underwriters may purchase up to an additional 2,250,000 shares under a 30-day option. If exercised in full, Vir expects net proceeds of approximately $161.5 million. Closing is expected on November 16, 2026, subject to customary closing conditions.
8-K Event Classification
Key Figures
Key Terms
underwriting agreement technical
underwriting discounts and commissions financial
gross proceeds financial
net proceeds financial
bookrunning managers technical
customary closing conditions technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much does VIR expect to raise in the offering?
When is VIR's offering expected to close?
AI-generated analysis. How Rhea-AI works. Not financial advice.